02:00 Mon 09 Aug 2021
Shield Therapeutics - AEGIS-CKD study results published in AJKD
Shield Therapeutics plc
("Shield or the "Company" or the "Group")
AEGIS-CKD study results published in American Journal of Kidney Disease
Ferric maltol demonstrates statistically significant (16 weeks) and sustained (up to 52 weeks) increase in haemoglobin, compared to placebo, in subjects with chronic kidney disease (CKD) and iron deficiency
anaemia (ID)
The double-blind randomised placebo-controlled Phase 3 study included adults with stage 3/4 CKD and mild to moderate iron-deficiency anaemia (IDA), who also had serum ferritin levels below 250 μg/L and transferrin saturation below 25% or ferritin levels below 500 μg/L and transferrin saturation below 15%. The paper concluded that the AEGIS-CKD trial shows that oral ferric maltol raises and sustains haemoglobin to provide iron for erythropoiesis in patients with eGFR as low as 30 mL/min/1.73 m2. Further, ferric maltol provides significant and sustained increases in iron storage indices, providing long-term control of IDA. In this population, ferric maltol was generally well tolerated, with a low rate of discontinuation due to adverse events. A drug such as ferric maltol that is able to replace and restore iron, that is orally administered, and that patients are able to tolerate will provide a clinically relevant treatment option for patients with moderate to severe CKD and anaemia due to iron deficiency
The publication can be found at https://pubmed.ncbi.nlm.nih.gov/34029682/
The lead author, Dr
For further information, please contact:
Shield Therapeutics plc |
+44 (0) 191 511 8500 |
||
|
|
||
|
|
||
Peel Hunt LLP - Nominated Adviser & Joint Broker |
+44 (0) 20 7148 8900 |
||
|
|
||
|
|
||
finnCap Ltd - Joint Broker |
+44 (0) 20 7220 0500 |
||
|
|
||
|
|
||
Walbrook PR - Financial PR & IR Adviser |
+44 (0) 20 7933 8780 |
||
|
|||
About Shield
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.
Shield's lead product, Feraccru®/Accrufer®, has been approved for use in
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE